These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10690558

  • 41. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [Abstract] [Full Text] [Related]

  • 42. Clinical trials referral resource. Clinical trials with tomudex.
    Sorensen JM, Cheson BD, Phillips PH.
    Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
    [No Abstract] [Full Text] [Related]

  • 43. The importance of p53-independent apoptosis in the intestinal toxicity induced by raltitrexed (ZD1694, Tomudex): genetic differences between BALB/c and DBA/2 mice.
    Pritchard DM, Bower L, Potten CS, Jackman AL, Hickman JA.
    Clin Cancer Res; 2000 Nov; 6(11):4389-95. PubMed ID: 11106258
    [Abstract] [Full Text] [Related]

  • 44. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
    Saga Y, Mizukami H, Suzuki M, Kohno T, Urabe M, Ozawa K, Sato I.
    Clin Cancer Res; 2002 May; 8(5):1248-52. PubMed ID: 12006545
    [Abstract] [Full Text] [Related]

  • 45. Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Samlowski WE, Lew D, Kuebler PJ, Kolodziej MA, Medina JE, Mangan KF, Moore DF, Schuller DE, Ensley JF.
    Invest New Drugs; 2002 May; 16(3):271-4. PubMed ID: 10360608
    [Abstract] [Full Text] [Related]

  • 46. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [Abstract] [Full Text] [Related]

  • 47. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 48. Interaction of tomudex with radiation in vitro and in vivo.
    Teicher BA, Ara G, Chen YN, Recht A, Coleman CN.
    Int J Oncol; 1998 Sep 01; 13(3):437-42. PubMed ID: 9683775
    [Abstract] [Full Text] [Related]

  • 49. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
    Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM.
    Mol Pharmacol; 2000 Mar 01; 57(3):453-9. PubMed ID: 10692484
    [Abstract] [Full Text] [Related]

  • 50. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB.
    Clin Cancer Res; 2008 Oct 01; 14(19):6228-36. PubMed ID: 18829502
    [Abstract] [Full Text] [Related]

  • 51. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
    Taguchi T, Kato Y, Baba Y, Nishimura G, Tanigaki Y, Horiuchi C, Mochimatsu I, Tsukuda M.
    Oncol Rep; 2004 Feb 01; 11(2):421-6. PubMed ID: 14719078
    [Abstract] [Full Text] [Related]

  • 52. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
    Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J.
    Clin Cancer Res; 2006 Jan 15; 12(2):556-62. PubMed ID: 16428500
    [Abstract] [Full Text] [Related]

  • 53. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
    Agrawal S, Kandimalla ER, Yu D, Hollister BA, Chen SF, Dexter DL, Alford TL, Hill B, Bailey KS, Bono CP, Knoerzer DL, Morton PA.
    Int J Oncol; 2001 May 15; 18(5):1061-9. PubMed ID: 11295057
    [Abstract] [Full Text] [Related]

  • 54. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C.
    Clin Cancer Res; 2004 Dec 15; 10(24):8665-73. PubMed ID: 15623651
    [Abstract] [Full Text] [Related]

  • 55. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.
    Shen J, Wang H, Wei J, Yu L, Xie L, Qian X, Zou Z, Liu B, Guan W.
    Int J Cancer; 2012 Sep 15; 131(6):E938-45. PubMed ID: 22422354
    [Abstract] [Full Text] [Related]

  • 56. Antitumor effects with apoptotic death in human promyelocytic leukemia HL-60 cells and suppression of leukemia xenograft tumor growth by irinotecan HCl.
    Chen YL, Chueh FS, Yang JS, Hsueh SC, Lu CC, Chiang JH, Lee CS, Lu HF, Chung JG.
    Environ Toxicol; 2015 Jul 15; 30(7):803-15. PubMed ID: 24474168
    [Abstract] [Full Text] [Related]

  • 57. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
    Takemura Y, Kobayashi H, Miyachi H.
    Int J Hematol; 2000 Jul 15; 72(1):112-4. PubMed ID: 10979221
    [No Abstract] [Full Text] [Related]

  • 58. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ.
    Clin Cancer Res; 1998 Mar 15; 4(3):743-53. PubMed ID: 9533544
    [Abstract] [Full Text] [Related]

  • 59. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
    Chen TC, Su S, Fry D, Liebes L.
    Cancer; 2003 May 01; 97(9 Suppl):2363-73. PubMed ID: 12712458
    [Abstract] [Full Text] [Related]

  • 60. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
    Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH.
    Clin Cancer Res; 2000 Dec 01; 6(12):4932-8. PubMed ID: 11156254
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.